Immunotherapy in EGFR-mutant non-small cell lung cancer.

Clin Exp Med · 2025 · PMC12628373 · PMID 41249684

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the second interim analysis, compared with chemotherapy alone, sintilimab in combination with IBI305 plus chemotherapy or combined with chemotherapy showed a trend toward a certain survival benefit (21.1 vs 20.5 vs 19.2 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.